Innovative Approach to Fecal Microbiota Transplantation (FMT) Applied for Chronic Kidney Disease (CKD)

  • STATUS
    Recruiting
  • participants needed
    10
  • sponsor
    Azienda Ospedaliero-Universitaria Consorziale
Send
Updated on 16 February 2024
See if I qualify
chronic disease
nephropathy
microbiota

Summary

The aim of this PhD project focuses on the relationship between intestinal microbiota and health in the background of Chronic Kidney Disease (CKD). Many pathologies, including the CKD, display a dysbiosis of the intestinal microbiota, which is at the same time a consequence of CKD and contributes to its progression and complication. In a variety of chronic-degenerative and infectious diseases, the "fecal microbiota transplantation" (FMT) is being tested in recent years in addition with the application of both probiotics and prebiotics. FMT is indeed currently successfully used in the eradication of recurrent Clostridium difficile infections, with success rates of 90%, thus recent evidence suggests that FMT could be applied in other diseases characterized by microbiota dysbiosis, such as CKD and diabetes, in which the FMT has never been previously tested.

This project will allow to study:

i) the prototypal production of the encapsulated suspension of healthy microbiota tested in a minimally invasive FMT procedure (by oral administration);

ii) the efficacy of the innovative prototype for colonization and modulation of intestinal microbiota following FMT;

iii) the experimental and clinical feedback of this suspension, by in vivo studies.

Description

This project will allow to experiment the Fecal microbiota transplantation in the CKD model and to set up a pharmaceutical formulation of fecal suspensions of microbiota.

Firstly, a collection of fecal samples from healthy volunteers will be set up, with the aim to collect biological samples. Screening and enrollment of healthy volunteers, gathering personal and clinical information together with eating habits, will be performed.

The best product design in efficacy, stability over time as well as suitable excipients and any other active components able to perform a synergistic action will be evaluated. After defining the pharmaceutical formulation, the production of the prototype will be finalized.

In a second time in vivo studies on a model of CKD (uremic mouse with CKD induced by 5/6 nephrectomy) will be designed and carried on. The CKD model will be used to evaluate the effects and the outcomes of FMT on clinical parameters such as renal function, circulating levels of uremic toxins, state and function of the intestinal microbiota, intestinal permeability and microbiota composition. This step will be necessary to establish the efficacy of the innovative prototype for the colonization and the modulation of intestinal microbiota following FMT.

Details
Condition Renal Failure, Renal Failure, Healthy
Age 18years - 50years
Clinical Study IdentifierNCT04222153
SponsorAzienda Ospedaliero-Universitaria Consorziale
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Healthy subjects
Aged between 18 and 50
BMI between 18.5-25
Omnivorous diet
Informed consent signed

Exclusion Criteria

Health workers (to exclude the risk of transmission of multi-resistant organisms)
Type 2 diabetes mellitus
Hypertension
Chronic liver disease
Chronic gastrointestinal disorders
Systemic inflammatory disorders
Suspected, clinical diagnosis or previous history of malignancies (<5 years)
Therapies with corticosteroids or immunosuppressive drugs
Autoimmune disorders
Previous history of organ / tissue transplantation
Prior gastrointestinal surgery (eg gastric bypass)
eGFR lower than 60ml / minute and / or diagnosis of nephropathy
Previous acute major cardiovascular diseases (myocardial infarction, stroke)
History of C. difficile infections
Known systemic infection not controlled
Previous use of antibiotics (<3 months)
Recent appearance of diarrhea
Chronic use of laxatives or chronic diarrhea
Chronic constipation
Recurrent urinary tract infections (3 cases per year)
Use of proton pump inhibitors in the last 3 months
Recent use of probiotics or other aids (drugs / supplements) for the regulation of gastrointestinal activity (<3 months)
Pregnancy and breastfeeding
Psychiatric conditions that reduce compliance
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

chronic disease
nephropathy
microbiota

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.